Dyve Biosciences utilizes its proprietary DMAX transdermal platform to deliver targeted pH modulation, effectively neutralizing the acidic microenvironments that promote cancer cell growth and inflammation in immunologic and oncologic diseases. This approach enhances the efficacy of existing therapies while providing a non-invasive delivery method for compounds that cannot be administered orally or via injection.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer and immunology therapies face challenges due to the acidic microenvironments surrounding tumors and inflamed tissues, which can promote disease progression and reduce treatment effectiveness. Oral or injectable administration of pH-modulating agents is often unsuitable due to tolerability issues or potential adverse events.
Solution
Dyve Biosciences utilizes its DMAX transdermal platform to deliver targeted pH modulation, directly addressing acidic microenvironments in immunologic and oncologic diseases. This non-destructive delivery method enhances the efficacy of existing therapies by neutralizing the acidity that drives cancer cell growth, immune evasion, and inflammation. The DMAX platform enables systemic bioavailability, avoids first-pass metabolism, and delivers molecules unsuitable for oral or injectable routes. By modulating tight junctions and fluidizing the skin's lipid matrix, DMAX achieves improved pharmacokinetics and allows for the delivery of pH modulators and other molecules that fall outside Lipinski’s Rules.
Target Audience
The primary target audience includes clinicians treating patients with solid tumors, acute gout, psoriasis, and other rheumatic joint and skin conditions where acidity plays a significant role in disease progression and inflammation.
Features
- DMAX transdermal platform for non-invasive delivery of pH-modulating agents
- Targeted pH modulation to neutralize acidic microenvironments in tumors and inflamed tissues
- Systemic bioavailability achieved through novel emulsion technology
- Capability to deliver molecules unsuitable for oral or injectable administration
- Improved pharmacokinetics compared to traditional delivery methods
- Lead products DYV800 (oncology) and DYV700 (rheumatology) in clinical development
- Potential to enhance the efficacy of existing immunotherapies and chemotherapies